quadazocine has been researched along with naloxonazine in 1 studies
| Studies (quadazocine) | Trials (quadazocine) | Recent Studies (post-2010) (quadazocine) | Studies (naloxonazine) | Trials (naloxonazine) | Recent Studies (post-2010) (naloxonazine) |
|---|---|---|---|---|---|
| 81 | 0 | 0 | 200 | 0 | 30 |
| Protein | Taxonomy | quadazocine (IC50) | naloxonazine (IC50) |
|---|---|---|---|
| Mu-type opioid receptor | Homo sapiens (human) | 0.0072 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.136 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.085 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gmerek, DE; Woods, JH | 1 |
1 other study(ies) available for quadazocine and naloxonazine
| Article | Year |
|---|---|
Effects of beta-funaltrexamine in normal and morphine-dependent rhesus monkeys: observational studies.
Topics: Animals; Azocines; Behavior, Animal; Dose-Response Relationship, Drug; Injections, Intraventricular; Injections, Subcutaneous; Macaca mulatta; Morphine; Muscle Relaxation; Naloxone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1985 |